The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1
- 11 March 2005
- journal article
- for debate
- Published by Springer Nature in Diabetologia
- Vol. 48 (4) , 608-611
- https://doi.org/10.1007/s00125-005-1704-8
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 DiabetesDiabetes, 2004
- Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2003
- The Influence of GLP-1 on Glucose-Stimulated Insulin SecretionDiabetes, 2003
- Chronic Inhibition of Circulating Dipeptidyl Peptidase IV by FE 999011 Delays the Occurrence of Diabetes in Male Zucker Diabetic Fatty RatsDiabetes, 2002
- Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in miceActa Endocrinologica, 2002
- The Origin and Function of the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)/Glucagon Superfamily*Endocrine Reviews, 2000
- Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidideMetabolism, 1999
- Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.Diabetes, 1998
- Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humansAmerican Journal of Physiology-Endocrinology and Metabolism, 1997
- Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.Journal of Clinical Investigation, 1993